AMENDMENT NO. 4Credit Agreement • February 20th, 2014 • Par Pharmaceutical Companies, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 4, dated as of February 20, 2014 (this “Amendment”), by and among PAR PHARMACEUTICAL COMPANIES, INC., a Delaware corporation (the “Parent Borrower”), PAR PHARMACEUTICAL, INC., a Delaware corporation (the “Co-Borrower” and, together with the Parent Borrower, the “Borrowers” and each a “Borrower”), SKY GROWTH INTERMEDIATE HOLDINGS II CORPORATION, a Delaware corporation (“Holdings”), the Subsidiary Guarantors party hereto, BANK OF AMERICA, N.A. (“BANA”), as administrative agent (in such capacity, the “Administrative Agent”), BANA, Goldman Sachs Bank USA (“Goldman”) and Deutsche Bank Securities Inc. (“DBSI”), as Lead Arrangers (collectively, the “Amendment No. 4 Lead Arrangers”) under the Credit Agreement, dated as of September 28, 2012 (as amended by Amendment No. 1, dated as of February 6, 2013, Amendment No. 2, dated as of February 20, 2013 and Amendment No. 3, dated as of February 28, 2013, the “Credit Agreement”), among the Parent Borrower, the Co-Borrower, Holdings, BAN
INCREMENTAL TERM B-2 LOAN JOINDER AGREEMENTLoan Joinder Agreement • February 20th, 2014 • Par Pharmaceutical Companies, Inc. • Pharmaceutical preparations • New York
JOINDER AGREEMENT, dated as of February 20, 2014 (this “Agreement”), by and among the Incremental Term Lender party hereto (the “Incremental Term B-2 Lender”), PAR PHARMACEUTICAL COMPANIES, INC. (the “Parent Borrower”), PAR PHARMACEUTICAL, INC. (the “Co-Borrower” and, together with the Parent Borrower, the “Borrowers”), the other Loan Parties party hereto, BANK OF AMERICA, N.A. (“BANA”), as Administrative Agent (in such capacity, the “Administrative Agent”), BANA and Goldman Sachs Bank USA (“Goldman” and, together with BANA, the “Lead Arrangers”).
